Regarding treatment, female HF patients were less frequently implanted with cardioverter-defibrillator (ICD) or cardiac resynchronization therapy (CRT), and less aggressively treated with angiotensin-converting enzyme inhibitors (ACEi), angiotensin II type 1 receptor blockers (AT1b), angiotensin receptor-neprilysin inhibitors (ARNI), diuretics, and, but only as a trend, less frequently received β-blockers and mineralocorticoid receptor antagonists (MRA). This evidence concerns the gene NR3C2 and hydrops fetalis.